Equity
€18,600 from €269,150 in 2021
Equity fell by 93% in 4 years.
DRSD
Lifetime
7 annual accounts with figures on one time axispeak €160,943 (2025)
€160,943▲ 53.7%
peak €119,736 (2025)
€119,736▲ 58.4%
peak €269,150 (2021)
€18,600unchanged
€142,018▲ 21.5%
Board1 name since 2019
1 director
Documentsfilings and deeds
29-05-202663 days before the deadline
2025micro format
Gross margin from €104,734 to €160,943Result from €75,568 to €119,736Dividend €119,736Debts from €116,842 to €142,018Cash from €87,718 to €122,848
Key points
from the 2025 annual accountsTurnover
≈ €300,000 estimated
The micro format states no turnover.
Debts
€142,018 88% of the balance sheet
Filings
7 annual accounts since 2019
The last five annual accounts were filed 0 to 63 days before the end of the period.
Starting capital
€18,600 186 shares
Position in the sector
11.6%
Lower solvency than 85% of companies in human health. Sector median 63.0% · 21,311 companies.
Checked score
Bankruptcy probability within 12 months
Financial strength
Score breakdown
Comparable companies, two years later
In July 2024, 6,715 companies had the same profile as DRSD has now. Each dot stands for 17 companies, two years later.
95.8%
were still trading
2.2%
stopped another way
1.8%
went bankrupt
Another 0.1% stopped without a precise date, possibly only after those two years.
Test of the method
The method was tested on the 497,762 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 2.9% | 3.1% |
| 10 | 5.6% | 6.1% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 6,715 companies, not a prediction for DRSD. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0717811282
Company renamed from Dr. Sofie Denkens to DRSD
Appointment: (director) · Gazette deed
Incorporation
Founding capital of €18,600, 186 shares, €12,400 paid up · Founder: (comparant) · Appointment: (manager) · published on 10-01-2019 · Gazette deed
First establishment
Dr. Sofie Denkens BVBA, Heihoefseweg 20, Edegem
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| DRSD Edegem | €160,618 | €160,943 | 11.6% | - |
| Dr.Peter Niemegeers Antwerp | €181,403 | €160,190 | 11.3% | - |
| JPG SURGERY Remicourt | €166,326 | €157,872 | 11.2% | - |
| Docteur Astrid NYSSEN Chaudfontaine | €166,842 | €167,513 | 11.4% | - |
| Ruth Lissens Keerbergen | €160,418 | €170,242 | 91.2% | - |
| Dr. Alexander Clarysse Kortrijk | €166,743 | €164,634 | 85.9% | - |
| DOKTER TINE CORNELIS Oud-Heverlee | €150,897 | €169,502 | 97.1% | 0 |
These companies have the same main activity as DRSD: specialist medical practice (NACE 86220). They are comparable in size and age: total assets between €151,000 and €181,000, founded in 2018.
Official details
Source: KBO- Status
- Active since 08-01-2019Normal situation
- Activity
- Specialist medical practiceNACE 86220and 1 other
- Establishment unit
- 2.283.712.6692650 Edegem, since 08-01-2019
- Financial year end
- 31 December
- Peppol
- Reachable since 15-12-2025
Annual accounts 2025
- €160,618▲ 18.6%
- Filing
- Filed on 29-05-2026, 63 days before the end of the filing period
Insights on DRSD
DRSD files the micro format. That format states no turnover. The gross margin rose from €136,087 in 2019 to €160,943 in 2025.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about DRSD
- What is the company number of DRSD?
- The company number of DRSD is 0717.811.282. The VAT number is the same number with BE in front: BE 0717.811.282.
- Where is DRSD based?
- The registered office is at Heihoefseweg 20, 2650 Edegem.Company details
- What does DRSD do?
- According to the KBO register, the main activity is specialist medical practice (NACE 86220).
- What is the legal form of DRSD?
- DRSD is a private limited company (BV).
- When was DRSD founded?
- DRSD was founded on 08-01-2019.
- Is DRSD still active?
- Yes, DRSD is an active enterprise in the KBO register.
- What is the turnover of DRSD?
- The turnover in financial year 2025 is ≈ €300,000. This figure is estimated from the gross margin of €160,943 and 40 comparable companies (NACE 86220). It probably lies between €250,000 and €400,000.Financials
- Is DRSD profitable?
- In financial year 2025, DRSD made a profit of €119,736.
- Where can I find the annual accounts of DRSD?
- DRSD filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of DRSD due?
- DRSD must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check See which support similar companies received that this one did not.Subsidies Compare this company with its sector.Sector benchmark
See how customers, suppliers and banks see your own company and what to improve first.